PATENT CLAIM ANALYSIS

Application Number: 16082753
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-02
Patent Classification: ["514", "386000"]

Abstract:
A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.

Claim (Index 14):
A method of treating cancer, viral or parasitic infections, central nervous system diseases, neuropsychiatric and neurodegenerative diseases, cerebrovascular disease, and immune-related disorders, comprising administering the compound or the pharmaceutically acceptable salt thereof according to  claim 1  to a patient in need of the treating.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 97.0
- Lexical Diversity: 1.62264
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15128874', '12265091', '16317245', '13393767', '15748557']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7940140872675951
- 35 USC 102 Novelty (BERT): 0.5382656196399074
- Combined Prediction Score: 0.7684392405048264
- Mean Citation Score: 347.380348
- Max Citation Score: 396.0309
- Similarity Product: 242.11261728183032

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test